Journal of Oncology / 2020 / Article / Tab 7

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 7

Response to second-line treatment according to the chemotherapy regimen.

ResponseSecond-line chemotherapy regimenTotal
Nab-paclitaxel/GemcitabineFOLFIRINOX/CAPOXIRIFOLFOX/CAPOXOther regimens

PRN (%)891322
25.045.06.323.525.9
SDN (%)1267732
37.530.043.841.237.6
PDN (%)1258631
37.525.050.035.336.5
TotalN (%)3220161785
37.623.518.820.0100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.